A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases
Authors
Keywords
-
Journal
EBioMedicine
Volume 90, Issue -, Pages 104539
Publisher
Elsevier BV
Online
2023-04-01
DOI
10.1016/j.ebiom.2023.104539
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression
- (2022) Christopher J. Nirschl et al. Cancer Immunology Research
- Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors
- (2022) Amanda M. Nash et al. Science Advances
- Organ-specific response after low-dose interleukin-2 therapy for steroid refractory chronic Graft-versus-Host Disease
- (2022) Haesook T Kim et al. Blood Advances
- Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.
- (2022) Ulka N. Vaishampayan et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
- (2022) Laura Codarri Deak et al. NATURE
- Interleukin-2–based therapies in cancer
- (2022) Miro E. Raeber et al. Science Translational Medicine
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases
- (2021) Hanna Graßhoff et al. Frontiers in Immunology
- 906P Simlukafusp α and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck
- (2021) A.R. Hansen et al. ANNALS OF ONCOLOGY
- Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
- (2021) Adi Diab et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).
- (2021) Jose Luis Perez-Gracia et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.
- (2021) Antoine Italiano et al. JOURNAL OF CLINICAL ONCOLOGY
- Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.
- (2021) Omid Hamid et al. JOURNAL OF CLINICAL ONCOLOGY
- An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism
- (2021) Jerod L. Ptacin et al. Nature Communications
- A Phase I Trial of the Antibody-Cytokine Fusion Protein F16IL2 in Combination with Anti-CD33 Immunotherapy for Posttransplant AML Relapse
- (2021) Andrew F. Berdel et al. BLOOD
- CUE-101, a Novel HPV16 E7-pHLA-IL-2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies
- (2020) Steven N Quayle et al. CLINICAL CANCER RESEARCH
- Defining the Threshold IL-2 Signal Required for Induction of Selective Treg Cell Responses Using Engineered IL-2 Muteins
- (2020) Aazam Ghelani et al. Frontiers in Immunology
- Interleukin-2 signals converge in a lymphoid–dendritic cell pathway that promotes anticancer immunity
- (2020) Miro E. Raeber et al. Science Translational Medicine
- Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study
- (2020) Evert Jan Van Limbergen et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer
- (2020) Dilara Sahin et al. Nature Communications
- De novo design of potent and selective mimics of IL-2 and IL-15
- (2019) Daniel-Adriano Silva et al. NATURE
- A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
- (2019) Salah-Eddine Bentebibel et al. Cancer Discovery
- Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
- (2019) Jing He et al. ANNALS OF THE RHEUMATIC DISEASES
- A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients
- (2019) Benjamin Weide et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease
- (2018) Laurence B. Peterson et al. JOURNAL OF AUTOIMMUNITY
- Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
- (2017) Christian Klein et al. OncoImmunology
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
- (2016) Elisabeth Quoix et al. LANCET ONCOLOGY
- Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2
- (2016) N. Arenas-Ramirez et al. Science Translational Medicine
- Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE
- (2015) Jens Y Humrich et al. ANNALS OF THE RHEUMATIC DISEASES
- Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study
- (2015) Riccardo Danielli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes
- (2015) Aixin Yu et al. DIABETES
- Interleukin-2 Activity Can Be Fine Tuned with Engineered Receptor Signaling Clamps
- (2015) Suman Mitra et al. IMMUNITY
- NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy
- (2015) Michel M van den Heuvel et al. Journal of Translational Medicine
- Interleukin-2: Biology, Design and Application
- (2015) Natalia Arenas-Ramirez et al. TRENDS IN IMMUNOLOGY
- The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer
- (2015) Chiara Catania et al. Cell Adhesion & Migration
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
- (2012) Mark R. Albertini et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
- (2012) Silke Gillessen et al. EUROPEAN JOURNAL OF CANCER
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264-272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies
- (2011) M. N. Fishman et al. CLINICAL CANCER RESEARCH
- A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
- (2011) T. K. Eigentler et al. CLINICAL CANCER RESEARCH
- A Low-Toxicity IL-2-Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
- (2011) S. D. Gillies et al. CLINICAL CANCER RESEARCH
- Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
- (2011) Elisabeth Quoix et al. LANCET ONCOLOGY
- Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
- (2011) David Saadoun et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
- (2011) John Koreth et al. NEW ENGLAND JOURNAL OF MEDICINE
- The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
- (2010) Manfred Johannsen et al. EUROPEAN JOURNAL OF CANCER
- Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
- (2010) Suzanne Shusterman et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
- (2010) C. Krieg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy
- (2008) J. Marlind et al. CLINICAL CANCER RESEARCH
- MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure
- (2008) R. Dreicer et al. INVESTIGATIONAL NEW DRUGS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More